Introduction
Unfortunately for Marinus Pharmaceuticals (MRNS) investors, the writing has been on the wall for awhile in regards to its only asset, ganaxolone. Management, after delays and lowered expectations, revealed interim phase 2 postpartum depression [PPD] data in December 2018. At this point I concluded:
Ganaxolone remains a long-shot for PPD, and very little value should be attributed to a valuation in Marinus.
Source: Clover Biotech Research
Share prices have actually bounced back a bit from that point, but things always work themselves out.
Marinus is down 60%+ upon the release of